Abstracts tagged "Comorbidity"

Abstract Number: 1909 • ACR Convergence 2024
Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
Insa Mannstadt¹, Yiyuan Wu² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: While systemic rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies, are known to have severe ophthalmologic manifestations, there…
Abstract Number: 0975 • ACR Convergence 2024
Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Sebastian E. Sattui¹, FRANK HARTMUT DR. BUTTGEREIT², Merav Lidar³, Kerri Ford⁴, Stefano Fiore⁵, Lita Araujo⁴, Timothy Beukelman⁶, Fenglong Xie⁷ and Jeffrey Curtis⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Charité University Medicine Berlin, Berlin, Germany, ³Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Bridgewater, NJ, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the…
Abstract Number: 1912 • ACR Convergence 2024
Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Cassie Clinton⁵, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: There is regional variation in the clinical characteristics, treatment, and outcomes of patients with inflammatory arthritis in the US. Despite a higher reported prevalence of…
Abstract Number: 1004 • ACR Convergence 2024
Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Ernesto Lopez Castillo¹ and Jeffrey Ording², ¹University of Colorado, Denver, CO, ²Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…
Abstract Number: 1986 • ACR Convergence 2024
Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
Juan Sevillano¹, Yixuan Zhou², Juan Ruiz³, Noha Abdel-Wahab⁴ and Maria Suarez-Almazor¹, ¹MD Anderson Cancer Center, Houston, TX, ²Baylor College of Medicine, Houston, ³MD Anderson, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…
Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Blanka Stiburkova¹, Aleš Kvasnička², Barbora Pisklakova², Jakub Rozhon², Karel Pavelka³ and David Friedecky², ¹Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ²Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic, ³Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…
Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: 0239 • ACR Convergence 2023
Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database
Michael Garshick¹, Haridarshan Patel², ada Kumar², Brian LaMoreaux², Lissa Padnick-Silver², Louis Dron³, Vinusha Kalatharan³, Vivek Verma³ and Michael Pillinger⁴, ¹NYU School of Medicine/NYU Langone Medical Center, New York, NY, ²Horizon Therapeutics, Deerfield, IL, ³Cytel Canada Inc., Vancouver, BC, Canada, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Gout is a common inflammatory arthropathy characterized by pain, joint swelling, and monosodium urate crystal deposits in joints, organs, and soft tissues.1 While gout…
Abstract Number: 1365 • ACR Convergence 2023
Extraglandular Involvement and Autoantibody Status as Risk Factors for Cardiovascular Disease in Primary Sjogren’s Syndrome (pSS): A 20 Year-follow up Study
Cristiana Sieiro Santos¹, Rúben Rego Salgueiro², Clara Moriano Morales³, Carolina Álvarez Castro³ and Elvira Díez Álvarez³, ¹Complejo Asistencial Universitario de León, León, Spain, ²ULS Guarda, Guarda, Portugal, ³CAULE, León, Spain
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disorder characterized by chronic multisystem inflammation with shared pathophysiology with SLE and RA. Cardiovascular events have emerged…
Abstract Number: 2314 • ACR Convergence 2023
Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus
Emma Materne¹, Baijun Zhou¹, Hyon K. Choi², Yuqing Zhang³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Adolescent-onset SLE is associated with more severe disease than adult-onset SLE, but young adults may also experience adverse outcomes. We sought to compare disease…
Abstract Number: 0249 • ACR Convergence 2023
Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination Survey
Hyemin Jeong and Chan Hong Jeon, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea
Background/Purpose: Gout is associated with several comorbidities. The aim of this study was to evaluate the prevalence of comorbidities in Korean adult population with gout.…
Abstract Number: 1442 • ACR Convergence 2023
Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus
Renata Baronaite Hansen¹, Julia Simard², Mikkel Faurschou¹ and Søren Jacobsen³, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Awareness of comorbidity in patients with SLE is increasing. Most studies to date have described comorbidity burden in prevalent SLE. We estimated the incidence…
Abstract Number: 2387 • ACR Convergence 2023
Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study
Nazanin Naderi¹, Aladdin Mohammad², Karin Wadström³, Ulf Bergström³ and Carl Turesson³, ¹Lund University, Kristiandstad, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: Manifestations of giant cell arteritis (GCA) include large vessel involvement (LVI) of the aorta and its branches. Aortic aneuryms are more common compared to…
Abstract Number: 0329 • ACR Convergence 2023
Factors Associated with Suicidal Ideation Among Patients with Inflammatory Rheumatic Musculoskeletal Disease: A Case-Control Study
Eike von Schlichting¹, Jan Dieris-Hirche², Imke Redeker³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²LWL-University Hospital, Department of Psychosomatic Medicine and Psychotherapy, Ruhr Universität Bochum, Bochum, Germany, ³Ruhr Universität Bochum, Bochum, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Mental health contributes to the morbidity of patients with inflammatory rheumatic musculoskeletal disease (iRMD). Despite extensive research conducted on the prevalence of depressive disorders,…
Abstract Number: 1480 • ACR Convergence 2023
Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region
Jamal Al-Saleh¹, Faisal Elbadawi¹, Rajaie Namas², Samar Al-Emadi³, Khalid A. Alnaqbi⁴, Humaid A. Al-Wahshi⁵, Amjad Alkadi⁶, Suad Hannawi⁷, Mohamed Hamouda⁸, Averyan Vasylyev⁸, Arwa Al-Shujairi⁸, Reem Al-Jayyousi⁹ and Munther Khamashta⁸, ¹Dubai Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Department of Rheumatology, Abu Dhabi, United Arab Emirates, ³Hamad Medical Corporation, Department of Rheumatology, Doha, Qatar, ⁴Tawam Hospital, Department of Rheumatology, Al Ain, United Arab Emirates, ⁵The Royal Hospital, Department of Rheumatology, Muscat, Oman, ⁶Ministry of Health, Kuwait, Kuwait, ⁷Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ⁸GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁹Mohamed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, United Arab Emirates, and Mediclinic Parkview, Dubai, United Arab Emirates
Background/Purpose: Data from limited studies of LN in the Gulf region suggest that LN manifests more severely in this region than in Caucasian populations, yet…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].